A Nature Biotechnology paper described an engineered UGA suppressor tRNA gene designed for AAV delivery that enables readthrough of UGA stop codons in vivo, broadening the class of genetic lesions addressable by a single vector strategy. The approach aims to convert nonsense mutations into full‑length proteins across multiple disease contexts, offering a disease‑agnostic payload modality. Authors showed in vivo activity and argued the suppressor tRNA could be applied across multiple monogenic disorders where UGA premature stop codons cause loss of function. Key translational questions include off‑target readthrough, long‑term expression, immunogenicity and manufacturing scale for AAV vectors carrying the tRNA cassette. If validated clinically, the platform could simplify payload design and speed program initiation for diverse rare diseases, but sponsors will need robust safety monitoring and precise biomarker strategies.